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Introduction
Tuberculosis, caused by the intracellular pathogen Myco-
bacterium tuberculosis, is one of the leading causes of mor-
bidity and mortality worldwide [1]. The bacilli
Calmette–Guerin (BCG) vaccine is an attenuated strain
of Mycobacterium bovis and represents the world’s most
widely used live vaccine, with more than two billion vac-
cinations performed to date [2]. BCG protects against
miliary tuberculosis in children [3], but fails to consis-
tently protect against pulmonary tuberculosis in adults,
the most prevalent form of the disease [4], with variabil-
ity of 0–80% [5].
Effective cell-mediated immunity is essential to con-
trol infection with M. tuberculosis. Many studies have
shown that major histocompatibility complex (MHC)
class I-restricted CD8+ cytotoxic T lymphocytes (CTL)
contribute to the control of M. tuberculosis infection by
mediating specific effector functions, which include lysis
of M. tuberculosis infected cells, killing of intracellular
pathogens and release of Th1 cytokines that activate
anti-mycobacterial mechanisms in macrophages [6]. In
humans, the MHC class I-restricted CD8+ T cells specific
for immunodominant epitopes derived from M. tuberculo-
sis proteins lyse infected cells and also release IFN-c upon
recognition of their targets [7, 8]. However, only a small
number of MHC class I-restricted CTL epitopes have
been identified within a few mycobacterial proteins. As
the antigen specificity of the human T-cell response is
known to be strongly controlled by HLA polymorphism
[9], the immunogenic potential of candidate vaccines
needs to be defined in the context of major HLA poly-
morphism. HLA-A2 is the most common HLA-A allele
in most of the populations, particularly in the Asian pop-
ulation with an estimated frequency of >40% [10]. As
tuberculosis affects many parts of Asia, identification of
HLA-A*0201-restricted CTL epitopes of M. tuberculosis
proteins is an important step towards vaccine design. The
prediction of epitopes that have the potential of eliciting
a CTL response has been greatly facilitated by the identi-
fication of binding motifs for different MHC class I
alleles.
Completion of the M. tuberculosis genome sequence
paved a way for the identification of many new candidate
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Abstract
CD8+ T cells are thought to play an important role in protective immunity
against tuberculosis. We report the identification of three peptides derived
from Rv1818c, Rv3812 and Rv3018c proteins of Mycobacterium tuberculosis that
bound to HLA-A*0201 molecules and their ability to induce in vitro T-cell
response in peripheral blood lymphocytes from HLA-A*0201-positive healthy
individuals (PPD+) and patients with TB. The peptide-specific cytotoxic
T lymphocytes (CTL) generated were capable of recognizing peptide pulsed
targets. Three 9-mer peptides bound with high affinity to HLA-A*0201 and
displayed low dissociation rates of the bound peptide from HLA. Epitope-spe-
cific recognition was demonstrated by the release of perforin and c-interferon.
Overall, our results demonstrate the presence of HLA class I-restricted CD8+
CTL against proteins from PE and PPE proteins of M. tuberculosis and identify
epitopes that are strongly recognized by HLA-A*0201-restricted CD8+ T cells
in humans. These epitopes thus represent potential subunit components for
the design of vaccines against tuberculosis.
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antigens for protective vaccine against tuberculosis. This
includes the discovery of two multigene families of pro-
teins PE and PPE. Members of PE and PPE protein fami-
lies are characterized by highly conserved N-terminal
domains and the C-terminus, which, however, show con-
siderable variation in the number of residues as well as in
the sequence [11]. Till date, little is known about the
functional role of the proteins of PPE or PE family in
the biology of M. tuberculosis. Recently, it has been shown
that rv1818c protein is loosely associated with the cell
wall and is localized on the outer membrane [12] and the
protein is released into the extracellular compartment
through exosomes secreted by dendritic cells or macro-
phages infected by M. tuberculosis [13]. It has also been
shown that the protein is taken up by T cells inducing
apoptosis [13].
In an earlier work, employing immuno-informatics
approach, we had identified a set of HLA class I-binding
peptides from these proteins. Further, their binding abili-
ties for HLA class I were ascertained using independent
methods such as molecular modelling and structural anal-
ysis [14]. This study has led to the identification of poten-
tial T-cell epitopes from PE and PPE proteins. We have
shown that one of the PE and PPE proteins, Rv1818c
protein induces good T-cell response in mouse models
[15]. We have also shown that Rv3812 (a PE_PGRS) and
Rv3018c (a PPE protein) are good T-cell antigens [16].
In this work, we have employed four peptides derived
from three PE ⁄PPE proteins predicted to bind to HLA-
A*0201 molecule with high affinity. Four peptides,
thus, identified to bind to HLA-A*0201 in silico were
experimentally tested for their ability to bind to the
HLA-A*0201 molecule ex vivo, and the ability of
HLA-A*0201-binding peptides to provoke in vitro T-cell
responses in peripheral blood mononuclear cell (PBMC)
preparations from HLA-matched healthy donors as well
as patients with tuberculosis. Our findings show that the
CTL generated in PBMC can elicit an antigen-specific,
HLA-A2-restricted response, effectively killing peptide-
pulsed T2 cells.
Materials and methods
HLA typing. Peripheral blood was collected from nine
people with HLA-A*0201. Five were healthy, BCG vac-
cinated and were all PPD positive. Four were suffering
from tuberculosis, as established by the presence of clini-
cal symptoms of TB, positive results of tuberculin (PPD)
skin testing and signs visible on chest radiography.
PBMC from patients with TB were obtained from Dr
Ambedkar Medical College Hospital, Bangalore, India.
PBMC were HLA typed by molecular typing using HLA
typing kit (Dynal Biotech Ltd, Olso, Norway) and HLA-
A*0201 sub-typing was accomplished by polymerase
chain reaction amplification technique using Sequence
Specific Oligonucleotide Primers. Formal consent was
obtained from all patients and the human experimenta-
tion guidelines of our institution were followed in the
conduct of clinical research.
Peptides. Peptides with high predicted half-time of
dissociation (t1 ⁄ 2) as predicted by BIMAS algorithm [17]
were purchased from Peptron (Peptron Inc., Daejeon,
South Korea) (Table 1). Two peptides which do not have
any binding motif for HLA-A*0201 were chosen as
negative controls, one peptide from Rv3812 490NY-
IPQQLAL498 and one peptide from Rv3018c 71AY-
VPYVAWL79. As a positive control for HLA-A*0201
binding ability, HLA-A*0201-restricted HTLV-tax pep-
tide 11LLFGYPVYV19 [18] was used.
Cell lines. Human transporter associated with antigen
processing (TAP)-deficient T2 cell line (kind gift from
Dr Franc¸ois Lemonnier, Unite´ Cellulaire Antivirale, Insti-
tut Pasteur, Paris) transfected with HLA-A*02 was
obtained and grown in RPMI-1640 medium supple-
mented with 10% FCS (RPMI ⁄10% FCS). The EBV-
transformed B-cell line JY (HLA type: A*0201, B7,
Table 1 The relative affinity of putative peptides for stable HLA-A*0201 molecules at the cell surface and the ability of the peptide to stabilize the
empty MHC class I molecules on cell surface of TAP deficient cells.
Protein Sequence AA position Stability HLA-A*0201 DT50 (h) IC50 (lM) Predicted t1 ⁄ 2 (min)
Rv1818c ALGGGATGV 385–393 7 1.4 69
Rv1818c TIPEALAAV 6–14 6 2.8 90
Rv3018c AQLLTEFAI 254–262 5 25 22
Rv3812 NLLVTGFDT 260–268 7 2.4 159
Rv3812 NYIPQQLAL 490–498 1 32 <1
Rv3018c AYVPYVAWL 71–79 1 28 <1
Jurkat cells were treated with acid for 5 min. Cells were immediately buffered with RPMI medium, re-suspended in the presence of 1.5 lg ⁄ml
b2-microglobulin and mixed with 150 nM of an FL-labelled reference peptide plus test peptide at a range of concentrations. After 12 h at 4 C, cells
were washed and analysed by flow cytometry. The mean fluorescence (MF) values obtained with the FITC-labelled peptide in the absence of competi-
tor peptide was taken as the maximal binding and equated to 0% inhibition. The MF value obtained without FITC-labelled peptide was taken as
being 100% inhibition. Relative binding affinity of the peptide was expressed as the peptide concentration needed to inhibit 50% of the binding of
the reference-labelled peptide (IC50). t1 ⁄ 2 represents the estimated half-time of dissociation of peptide as predicted by BIMAS algorithm.
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Cw7, kind gift from Dr Linda Sherman, TSRI, La Jolla,
CA, USA) was grown in RPMI-1640 medium supple-
mented with 10% FCS.
HLA-A*0201 peptide binding and complex stability
assay. To determine weather synthetic peptides could
bind to HLA-A*0201 molecules, peptide-induced HLA-
A*0201 upregulation on T2 cells was examined as
described earlier [19]. Briefly, T2 cells were incubated at
25 C for 16 h, and further incubated with 100 lM of
peptides for 1 h at 25 C and 2 h at 37 C. Cells were
then washed to remove unbound peptides and incubated
at 37 C for 0, 2, 4, 6 and 12 h after peptide with-
drawal. Subsequently, the expression of HLA-A*0201 on
T2 cells in the absence of exogenous peptide was mea-
sured by flow cytometry using fluorescein isothiocyanate
(FITC)-conjugated monoclonal antibody BB7.2 (eBio-
science, San Diego, CA, USA). The increase in HLA-
A*0201 expression on T2 cells reflects the stabilization
of MHC by the addition of exogenous peptides and for
each time point, peptide-induced HLA-A*0201 expres-
sion was calculated as (mean fluorescence of peptide-pre-
incubated T2 cells mean fluorescence of T2 cells treated
in similar conditions in the absence of peptide). DC50
(dissociation complex, DC) was defined as the time
required for the loss of 50% of the HLA-A*0201 ⁄pep-
tide complexes stabilized at t = 0. The definitive DC50
value for each peptide was determined from at least three
independent experiments.
A second, competition-based HLA-A2 peptide bind-
ing assay using JY-EBV cells was performed as described
previously [20]. In short, HLA molecules on JY-EBV
cells were stripped via a mild acid treatment. Stripped
cells were subsequently incubated with various concentra-
tions of peptides for 24 h at 4 C in the presence of
150 nM of a fluorescein (FL)-labelled reference peptide
[FLPSDC(-FL)FPSV] and 1.5 lg ⁄ml human b2-micro-
globulin, and analysed by flow cytometry. The binding
capacity of a peptide is expressed as the concentration
required for inhibiting 50% of the binding of the
FL-labelled reference peptide (IC50).
Generation of CTL in PBMC donors. To generate poly-
clonal CTL, 2 · 106 PBMC from HLA-A2-positive donors
were isolated from whole blood by Ficoll ⁄Hypaque (Sigma,
St Louis, MO, USA) density gradient centrifugation. The
PBMC were co-cultivated for 7 days with irradiated
(5000 rad) autologous PBMC prepulsed with synthetic
peptides (10 lg ⁄ml). On every third day, IL-2 was added
(100 U ⁄well; eBioscience). After 2 weeks of culture, the
cells were employed for further experiments.
Intracellular IFN-c measurement using flow cytometry.
Peripheral blood mononuclear cells (2 · 106 per ml) from
donors were cultured in 96-well tissue culture plates in
the presence of 20 lg of protein ⁄ml for 1 or 3 days. Bre-
feldin A (10 lg ⁄ml; Sigma) was added to the cultures
for the last 5 h to prevent secretion of the intracellular
cytokine. One million cells from each group were first
incubated with FITC-conjugated anti-CD8 Ab (clone
RPA-T8; eBioscience) for 30 min at 4 C. Cells were
washed, fixed with 4% paraformaldehyde, and permeabi-
lized with 0.1% saponin. Cells were incubated with PE
conjugated anti-IFN-c Ab (clone 4S.B3; eBioscience) for
30 min at 4 C, washed, and acquired on a cytofluoro-
meter (FACSCALIBUR; BD, Mountain View, CA, USA).
An analysis was carried out using Cell Quest software.
Human IFN-c ELISPOT assay. An ELISPOT analysis
for IFN-c secretion using human PBMC was carried out
as previously described [21].
CTL assay. A cytotoxic T lymphocyte assay was per-
formed employing a non-radioactive method, based on
the release of LDH from target cells as described earlier
[22]. Briefly antigen-specific CTL were collected from
in vitro expanded culture and washed once with RPMI-
1640. Viable cells were purified by ficoll density gradient
centrifugation and re-suspended in RPMI medium. T2
target cells were incubated with the peptides (10 lg ⁄ml)
for 2 h at 37 C. After washing, 5 · 103 cells ⁄100 ll
were added to 100 ll of various numbers of effector cells
that had been plated in 96-well plates to get a target-
to-effector ratio of 1:20, 1:40 and 1:100. The medium or
the target cells alone were kept as low control (Spontane-
ous LDH release). For the high control (maximum LDH
release), 2% of Triton X 100 was added to the target
cells .The cells were incubated for 12 h. Afterwards,
100 ll of culture the culture supernatant is collected
cell-free and assayed for LDH release by Cytotoxicity
Detection Kit-LDH (Roche Applied Science, Mannheim,
Germany). The percentage cell-mediated cytotoxicity was
determined by the following equation:
Statistical analysis. The statistical significance of differ-
ential findings between experimental groups was deter-
mined by Student’s t-test. Data were considered
statistically significant at P < 0.05.
Cytotoxicity ð%Þ ¼ ðeffector target cell mix effector cell controlÞ  lowcontrol
high control low control
 
 100
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Results
Identification of HLA-A2-binding peptides within
PE and PPE proteins
To identify potential HLA-A2-restricted epitopes within
Rv3812 and Rv3018c, the amino acid sequence was analy-
sed by a computer program designed to predict HLA-bind-
ing peptide, based on an estimation of the half-time of
dissociation of the HLA-peptide complex. Four peptides
earlier identified [14] to bind to HLA-A*0201 allele
employing predictive algorithms were chosen (Table 1).
These peptides were then analysed for their capacity to sta-
bilize HLA-A*0201 molecules on the surface of the anti-
gen-processing deficient cell line T2. The T2 cells were
incubated with the relevant peptide and the resultant
increase in the cell surface expression of HLA-A*0201 was
measured. In this assay, a nonamer peptide from HTLV-
Tax protein (11LLFGYPVYV19), which has a high binding
affinity for the HLA-A*0201 molecule [19], was used as
positive control. This peptide resulted in a sixfold increase
in cell surface HLA-A*0201 stabilization (Fig. 1).
The highest level of stabilization was observed with
Rv3812 Peptide260–268, Rv1818c Peptide385–393 and
Rv1818c Peptide6–14 for more than 6 h. The two nega-
tive control peptides could not stabilize the peptide–
MHC complex for more than 1 h (Table 1).
The relative affinity of all the peptides bearing the
motif for HLA-A*0201 molecule was then determined
using a competition-based HLA class I-binding assay [20].
In this assay, the lymphoblastoid cell line JY, was used
after acid treatment, aimed to remove the peptides from
HLA molecules present on its surface. These stripped cells
were then incubated with a mixture of a fixed amount of a
fluoresceinated reference peptide, and different concentra-
tions of the four peptides under test. Peptides with affinity
for the HLA-A*0201 molecule will compete for the bind-
ing of the fluoresceinated reference peptide. Three peptides
showed high IC50 < 5 mM (Table 1). Although the T2 sta-
bilization assay measures the stability of binding, the pep-
tide binding competition assay determines those peptides
which bind faster and compete better.
Stimulation of PE and PPE peptide-specific T cells in vitro
We evaluated the ability of four PE and PPE-derived
peptides, which showed reproducibility of binding to
HLA-A*0201 molecules as judged by two independent
methods, for their ability to elicit antigen-specific T-cell
response. To achieve this, PBMC from healthy and tuber-
culosis-infected HLA-A*0201 individuals were isolated
and stimulated in vitro with peptides. Three of the pep-
tides that displayed relatively high binding affinity for
HLA-A*0201 molecules were able to induce peptide-spe-
cific stimulation of PBMC both in healthy donors and
patients with TB (Fig. 2A and B). At the same time, the
non-HLA-A*0201-restricted negative control peptides
induced little or no stimulation of PBMC (Fig. 2). How-
ever, upon stimulation with the peptides, the in vitro
proliferation of patient PBMC was lesser compared with
healthy control PBMC.
Cytotoxic activity of peptide-specific T cells
We investigated whether these peptides would trigger
specific and functional CTL responses in HLA-A*0201-
positive donors, both healthy and patients with TB.
PBMC from donors were isolated and stimulated in vitro
with peptides. The cytotoxic activity of the responding
cells was measured after two consecutive stimulations
against T2 cells pulsed with the peptides used in the
stimulations. In both healthy patients and TB HLA-
A*0201-positive donors tested, peptide-specific CD8+ T
cells were generated that specifically lysed peptide-pulsed
T2 cells (Table 2). But the specific lysis of the target
cells by PBMC from healthy individuals was significantly
more than that induced by PBMC from patients with TB
(P = 0.003). The peptide specificity of the target cells
was clearly demonstrated as target cells loaded with
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Figure 1 Stability of peptide bound to major histocompatibility
complex class I (HLA-A*0201) molecules on T2 cells. (A) (•) Rv3812
Peptide260–268, ( ) Rv3018c Peptide254–262, ( ) Positive control pep-
tide-LLFGYPVYV, (D) No Peptide. (B) (•) Rv1818c Peptide6–14, ( )
Rv1818c Peptide385–393 ( ) Positive control peptide-LLFGYPVYV, (D)
No peptide. The results are expressed as mean fluorescence intensity. T2
cells were incubated for 16 h at 25 C, washed and incubated with pep-
tides for different time points. The cells were then washed and stained
with FITC-conjugated MoAb directed against HLA-A*0201. Results
are representative of three independent experiments. Data represent
mean ± SD.
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irrelevant peptides were not lysed. HLA restriction was
demonstrated by the lack of lysis of HLA-A*0201-
mismatched target cells (data not shown). Moreover,
the peptide-specific cytolysis of targets was inhibited by
anti-MHC class I MoAb, thus corroborating the MHC
class I restriction and CD8 dependency of these effector
cells.
Effector function of antigen-specific T cells
Production of Th1 type of cytokines is an essential effector
function of T cells responding to bacterial infections in
humans and mice [22]. We tested whether peptide-specific
CTL can release IFN-c, from in vitro expanded PBMC from
HLA-A*0201-positive individuals when challenged with
the peptides by an ELISPOT assay. The predominant
response was seen for Rv3812 Peptide260–268, with a much
reduced response to Rv1818c Peptide6–14 and Rv1818c
Peptide385–393 and very low response to Rv3018c Pep-
tide254-262. The response was HLA-A*0201 mediated as
shown by the inhibition of response by anti HLA-A2 anti-
bodies (Table 3). The frequencies of cytokine-producing
CD8+ T cells among effectors were determined by intracel-
lular cytokine staining. The frequency of epitope-specific
CD8+ T cells positive for IFN-c was the highest for
Rv3812 Peptide260–268 ranging from 8% to 12% and
Rv1818c Peptide385-393 ranging from 8% to 14% in dif-
ferent individuals (Table 4). All the in vitro expanded pep-
tide-specific T cells, more by healthy donors, induced a
good number of CD8+ T cells secreting INF-c on stimula-
tion with the corresponding peptides, which followed the
pattern of CTL assay. The negative control Rv3812 Pep-
tide490–498 Rv3018c Peptide71–79 induced peptide-specific
CD8+ T cells positive for IFN-c ranging from 1.2% to
3.8% and from 2% to 2.8% respectively.
Discussion
Cellular immunity mediated by CD4+ T cells as well as
MHC class I-restricted CD8+ T cells are important for pro-
tective immunity against tuberculosis as mice lacking
functional CD8+ T cells were more susceptible to tubercu-
losis, b2-microglobulin deficiency are more susceptible to
MTB [23–25]. In this work, we have employed PE ⁄PPE
protein-derived epitopes with high affinity for HLA-
A*0201 molecules identified, using computational meth-
ods and verified by MHC peptide binding assays. Four
peptides from Rv1818c, Rv3812 and Rv3018c of PE ⁄PPE
family were recognized by T cells from HLA-A*0201-
typed PPD-positive healthy donors and patients with TB.
The peptide-specific responses were studied in vitro by test-
ing CTL responses of T cells from HLA-A*0201-matched
healthy donor PBMC. CTL generated in response to pep-
tides from the chosen three proteins secreted IFN-c and
killed target cells in peptide-specific and HLA-A*0201-
restricted manner. Peptides derived from PE ⁄PPE proteins
could induce significant CTL responses in PBMC from
healthy human donors compared with patients with TB,
Table 2 Cytotoxic response of antigen-specific T cells.
Patients with TB PPD-positive healthy donors
1818pep6–14 32 ± 8 68 ± 14
1818pep385–393 57 ± 14 77 ± 11
3812pep260–268 28 ± 11 68 ± 13
3018pep254–262 55 ± 10 66 ± 14
3812pep490–498 18 ± 5 17 ± 8
3018pep71–79 22 ± 9 24 ± 9
PBMC from HLA-A*0201 donors were in vitro expanded in the pres-
ence of the peptides (10 lg ⁄ml). The ability to induce CTL was tested
by performing cytotoxicity assay against different numbers of target
cells, antigen-stimulated T2 cells. % of specific lysis was measured for
different effectors and target ratio. % lysis of unpulsed T2 cells by
PBMC was the negative control. Results are representative of three
independent experiments. Data represent mean ± SD. The specific lysis
by T-cell lines from healthy controls was significantly higher than that
induced by T-cell lines from patients with TB (P = 0.003).
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Figure 2 In vitro T-cell proliferative response
specific for HLA-A*0201-binding peptides.
(A) HLA-A*0201-typed human PBMC were
in vitro re-stimulated with synthetic peptides
(10 lg ⁄ml) pulsed T2 cells (1 · 104) for
96 h and tested for the T-cell proliferation.
Results are presented as mean ± standard
deviations of pooled response of three
independent experiments. Each bar represents
T-cell response to each HLA-A*0201 indi-
vidual. (A) PPD-positive healthy controls. (B)
Patients with TB.
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suggesting that CTL precursor populations against these
mycobacterial peptides exist at a higher frequency within
the T-cell repertoire of healthy individuals. Reduced CTL
activity, IFN-c production shown by peptide-specific
T-cell lines derived from patients with TB in comparison
with peptide-specific T-cell lines from healthy donors
strongly suggests that the CD8+ T-cell epitopes of the
three proteins may have a role in protective immunity.
Our results are in agreement with the earlier reported
observations of preferential T-cell responses to Ag85 com-
plexes [26, 27] and Apa protein of M. tuberculosis [28]. CTL
reactivity is considered to be protective in the control of
M. tuberculosis growth. Using an intracellular assay for
assessing IFN-c production to measure peptide-specific
CD8+ T-cell frequencies, we demonstrated that CD8+
T-cell responses to the chosen peptides are detected ex vivo
in PBMC, which indicates that the CD8+ T-cell response
to these peptides may be elicited during the course of
M. tuberculosis infection in vivo.
One of the possible obstacles of any epitope-based
approach to vaccination in humans is HLA polymorphism
because choice of epitopes is allele specific. However, this
obstacle might be overcome using appropriate mixtures of
synthetic peptide epitope or by constructing vectors to
express polypeptides in which the relevant epitope
sequences are linearly joined together. More recently,
work in a murine model has also shown that each of sev-
eral CTL epitopes combined in a polyepitope construct
was capable of eliciting a CTL response in vivo in animal
models [29]. In the long term, it may be possible to com-
bine CTL epitopes from the PE and PPE proteins with
other mycobacterial antigens generating a chimeric pro-
tein that fuses the important immunogenic determinants
from different types of antigens to design an effective vac-
cine. It is important to mention here that although the
result from the present work does not lead to any firm
conclusions on the efficacy of a PE ⁄PPE epitope-based
vaccine in humans, it does clearly show that CTL epitopes
from these two classes of proteins can be used as immuno-
gens to induce an efficient CTL response in vivo. Earlier it
has been shown that HLA-A*0201-binding nonamer pep-
tides derived from the acr ⁄16-kDa antigen (Rv2031c),
19-kDa lipoprotein (Rv 3763), superoxide dismutase
(Rv3846), alanine dehydrogenase (Rv2780) and glutamine
synthetase (Rv2220) of M. tuberculosis elicit cytotoxic
CD8+ T cells from patients with TB [30–33]. Epitope-
specific recognition was demonstrated by the lysis of both
M. tuberculosis-infected and peptide-pulsed macrophages,
the release of cytotoxic granules and IFN-c production.
In conclusion, our study has identified novel HLA-
A*0201-restricted, immunogenic T-cell epitopes of
Rv1818c, Rv3812 and Rv3018c proteins of PE ⁄PPE
Table 3 Functional activity of peptide-specific
human A*0201-typed T-cell lines.SFC (per 10
6 cells) (ELISPOT),
patients with TB
SFC ( ⁄ 106 cells) (ELISPOT),
PPD-positive healthy donors
Antigen
Anti-HLA-A2
MoAb Antigen
Anti-HLA-A2
MoAb
1818pep6–14 88 ± 12 22 ± 8 125 ± 31 122 ± 22
1818pep385–393 187 ± 44 27 ± 10 324 ± 47 85 ± 14
3812pep260–268 202 ± 27 49 ± 10 342 ± 54 54 ± 9
3018pep254–262 147 ± 32 51 ± 11 250 ± 34 47 ± 11
3812pep490–498 65 ± 28 64 ± 12 72 ± 18 62 ± 35
3018pep71–79 42 ± 12 42 ± 15 112 ± 21 92 ± 22
Production of IFN-c in response to stimulation with PE ⁄ PPE peptides. Human PBMC were
in vitro expanded in the presence of synthetic peptides (10 lg ⁄ml) Primed T cells (4 · 105 per
well) were in vitro expanded in the presence of T2 (1 · 105 per well) pulsed with peptides as APC
and in the presence of monoclonal antibodies to HLA-A2. After 24 h of stimulation, spot forming
cells were counted (SFC) by an ELISPOT. Data represent mean ± SD.
Table 4 Intracellular IFN-c staining of antigen-specific T cells from five HLA-A*0201-typed PBMC of healthy controls and patients with TB.
IFN-c-secreting CD8+ T cells (%)
HD1 HD2 HD3 HD4 HD5 TP1 TP2 TP3 TP4
Un-stimulated 0.11 ± 0.04 0.22 ± 0.02 2.3 ± .05 0.44 ± 0.04 0.88 ± 0.04 0.3 ± 0.05 0.13 ± .05 0.2 ± 0.04 1.3 ± .05
Rv1818 pep6–14 6.5 ± 1.2 5.8 ± 2.7 11.2 ± 0.8 9 ± 2.8 2.4 ± 0.34 3.5 ± 0.45 2.3 ± 0.35 2.6 ± 1.4 2.4 ± 3.2
Rv1818 pep385–393 8.5 ± 1.8 8.8 ± 2.3 14 ± 1.4 11.2 ± 2.2 12.2 ± 1.6 4.1 ± 1.1 4.3 ± 1.2 8.8 ± 3.5 5.7 ± 1.5
Rv3812 pep260–268 8.2 ± 2.1 11.9 ± 1.4 9.4 ± 2.7 12.2 ± 3.1 9.5 ± 1.1 5.7 ± 1.5 5.3 ± 1.2 3.8 ± 1.1 2.3 ± 0.2
Rv3018c pep254–262 7.9 ± 1.3 3.5 ± 1.4 6.4 ± 0.9 9.5 ± 2.4 3.5 ± 1.5 2.7 ± 1.7 1.3 ± 0.4 2.2 ± 1.5 1 ± 0.23
Percentage of CD8+ T cells secreting IFN-c was determined by doing a double staining for surface CD8 and intracellular IFN-c using FACSscan.
Results are representative of three independent experiments. HD, healthy donors; TP, patients with TB.
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family of M. tuberculosis. These newly identified epitopes
may help in the design of a better vaccine candidate
against tuberculosis.
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